DAUNORUBICIN Drug Patent Profile

Which patents cover Daunorubicin, and when can generic versions of Daunorubicin launch?

Daunorubicin is a drug marketed by Fresenius Kabi Usa, Hikma, Hisun Pharm Hangzhou, Meitheal, and Teva Parenteral. and is included in seven NDAs.

The generic ingredient in DAUNORUBICIN is daunorubicin hydrochloride. There are eleven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the daunorubicin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Daunorubicin

A generic version of DAUNORUBICIN was approved as daunorubicin hydrochloride by HIKMA on January 30^th, 1998.

Summary for DAUNORUBICIN

US Patents:	0
Applicants:	5
NDAs:	7
Drug Prices:	Drug price information for DAUNORUBICIN
DailyMed Link:	DAUNORUBICIN at DailyMed

See drug prices for DAUNORUBICIN

US Patents and Regulatory Information for DAUNORUBICIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Fresenius Kabi Usa	DAUNORUBICIN HYDROCHLORIDE	daunorubicin hydrochloride	INJECTABLE;INJECTION	065034-001	Nov 20, 2001		DISCN	No	No
Teva Parenteral	DAUNORUBICIN HYDROCHLORIDE	daunorubicin hydrochloride	INJECTABLE;INJECTION	064212-001	Jun 23, 1998		DISCN	No	No
Hisun Pharm Hangzhou	DAUNORUBICIN HYDROCHLORIDE	daunorubicin hydrochloride	INJECTABLE;INJECTION	208759-001	Apr 12, 2019	AP	RX	No	No
Teva Parenteral	DAUNORUBICIN HYDROCHLORIDE	daunorubicin hydrochloride	INJECTABLE;INJECTION	064212-002	May 3, 1999		DISCN	No	No
Fresenius Kabi Usa	DAUNORUBICIN HYDROCHLORIDE	daunorubicin hydrochloride	INJECTABLE;INJECTION	065000-001	May 25, 1999	AP	RX	No	No